What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2023-05-15 compared with 2022-11-14 · 29 added, 20 removed, 14 unchanged (78% of the section changed)

Other Information

As discussed, above, the Company’s

daily operations are also managed in part by personnel employed by PAVmed, for which the Company incurs a service fee, referred to as

the “MSA Fee”, according to the provisions of a Management Services Agreement (“MSA”) with PAVmed.

2023, the Company and PAVmed entered into a seventh amendment to the MSA to increase the MSA Fee to $0.75 million per month, effective

January 1, 2023.

exhibits filed as part of this Quarterly Report on Form 10-Q are set forth in the “ Exhibit Index ” below.

2 unchanged sentences

Diagnostics Inc.

November 14, 2022

Dennis M McGrath

1 unchanged sentence

Financial and Accounting Officer)

Incorporation

Purchase Agreement, dated as of February 25, 2022, by and among LucidDx Labs Inc., Lucid Diagnostics Inc.

Incorporation by Reference

Form of Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock

Form of Senior Secured Convertible Promissory Note

Termination Agreement, dated as of February 10, 2023, by and among Lucid Diagnostics Inc., LucidDx Labs Inc.

and ResearchDx, Inc.

and Restated 2018 Long-Term Incentive Equity Plan.

Stock Purchase Plan

Certification

of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification

of Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification

of Principal Executive Officer pursuant to 18 U.S.C.

Registration Rights Agreement, dated as of March 7, 2023, by and among Lucid Diagnostics Inc.

and the purchases of Series A Preferred Stock party thereto

Form of Securities Purchase Agreement

Form of Guaranty

Form of Registration Rights Agreement

Form of Voting Agreement

Seventh Amendment to Management Services Agreement, dated as of May 9, 2023, by and between PAVmed Inc.

and Lucid Diagnostics Inc.

Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of Principal Executive Officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Certification

of Principal Financial and Accounting Officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley

XBRL Instance Document

XBRL Taxonomy Extension Schema

XBRL Taxonomy Extension Calculation Linkbase

XBRL Taxonomy Extension Label Linkbase

XBRL Taxonomy Extension Presentation Linkbase

Page Interactive Data File (embedded within the Inline XBRL document)

Certification of Principal Financial and Accounting Officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Inline XBRL Instance Document

Inline XBRL Taxonomy Extension Schema

Inline XBRL Taxonomy Extension Calculation Linkbase

Inline XBRL Taxonomy Extension Label Linkbase

Inline XBRL Taxonomy Extension Presentation Linkbase

Cover Page Interactive Data File (embedded within the

Inline XBRL document)

Filed herewith.

3 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information